Crinetics Pharmaceuticals (CRNX) Competitors

In the previous week, Moderna had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 10 mentions for Moderna and 5 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.32 beat Moderna's score of 0.15 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Crinetics Pharmaceuticals has higher earnings, but lower revenue than Moderna. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Moderna has a net margin of -143.55% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Moderna's return on equity of -26.64% beat Crinetics Pharmaceuticals' return on equity.

Crinetics Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals currently has a consensus price target of $78.27, indicating a potential downside of 6.69%. Moderna has a consensus price target of $38.80, indicating a potential downside of 36.72%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Moderna.

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 2.31%. Crinetics Pharmaceuticals has a consensus target price of $78.27, indicating a potential downside of 6.69%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Crinetics Pharmaceuticals.

Roivant Sciences has higher revenue and earnings than Crinetics Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

In the previous week, Roivant Sciences had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 5 mentions for Crinetics Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.09 beat Crinetics Pharmaceuticals' score of 0.32 indicating that Roivant Sciences is being referred to more favorably in the media.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals has a net margin of -2,747.18% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Crinetics Pharmaceuticals' return on equity.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Insmed had 13 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 18 mentions for Insmed and 5 mentions for Crinetics Pharmaceuticals. Insmed's average media sentiment score of 0.96 beat Crinetics Pharmaceuticals' score of 0.32 indicating that Insmed is being referred to more favorably in the news media.

Crinetics Pharmaceuticals presently has a consensus target price of $78.27, suggesting a potential downside of 6.69%. Insmed has a consensus target price of $209.91, suggesting a potential upside of 93.16%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Crinetics Pharmaceuticals.

Insmed has a net margin of -144.44% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Insmed's return on equity.

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Crinetics Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

BioNTech presently has a consensus price target of $129.13, suggesting a potential upside of 40.09%. Crinetics Pharmaceuticals has a consensus price target of $78.27, suggesting a potential downside of 6.69%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts clearly believe BioNTech is more favorable than Crinetics Pharmaceuticals.

In the previous week, BioNTech had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 6 mentions for BioNTech and 5 mentions for Crinetics Pharmaceuticals. BioNTech's average media sentiment score of 0.62 beat Crinetics Pharmaceuticals' score of 0.32 indicating that BioNTech is being referred to more favorably in the media.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioNTech has a net margin of -44.39% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. BioNTech's return on equity of -5.30% beat Crinetics Pharmaceuticals' return on equity.

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Crinetics Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.